10,845 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by GKV Capital Management Co. Inc.

GKV Capital Management Co. Inc. bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,845 shares of the medical research company's stock, valued at approximately $2,827,000. Amgen accounts for 1.2% of GKV Capital Management Co. Inc.'s holdings, making the stock its 26th largest position.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Centricity Wealth Management LLC acquired a new position in Amgen during the 4th quarter valued at about $25,000. Ritter Daniher Financial Advisory LLC DE lifted its stake in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares during the period. Synergy Investment Management LLC acquired a new stake in Amgen during the 4th quarter worth about $34,000. Atala Financial Inc acquired a new position in shares of Amgen in the fourth quarter valued at about $34,000. Finally, Heck Capital Advisors LLC purchased a new position in shares of Amgen in the fourth quarter worth about $36,000. Institutional investors own 76.50% of the company's stock.

Amgen Stock Up 1.2 %

Shares of Amgen stock traded up $3.19 during trading hours on Tuesday, hitting $276.87. The company had a trading volume of 559,525 shares, compared to its average volume of 3,192,634. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a market cap of $148.86 billion, a P/E ratio of 36.69, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company's 50-day moving average is $302.62 and its two-hundred day moving average is $293.55.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.44%. Amgen's payout ratio is currently 126.09%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on AMGN. UBS Group boosted their target price on shares of Amgen from $315.00 to $319.00 and gave the company a "neutral" rating in a research report on Monday, April 14th. Morgan Stanley boosted their price objective on Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 9th. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Piper Sandler Companies reissued an "overweight" rating and issued a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Finally, StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $310.57.

Insider Transactions at Amgen

In related news, EVP David M. Reese sold 25,225 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 in the last ninety days. 0.69% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.